HC Wainwright Reiterates Buy Rating for Prothena (NASDAQ:PRTA)

Prothena (NASDAQ:PRTA – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $48.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential upside of 208.48% from the stock’s […]

Leave a Reply

Your email address will not be published.

Previous post Stifel Nicolaus Raises Guardant Health (NASDAQ:GH) Price Target to $53.00
Next post Stifel Nicolaus Boosts Insulet (NASDAQ:PODD) Price Target to $293.00